ERBB2 and breast cancer: Since patients with HER2+ BC may respond differently to HER2-targeted therapies due to heterogeneity, we thus simulated four phenotypes with distinct response patterns to treatments by adjusting parameters based on the results of sensitivity analyses (Fig. 6d).